Business Context and Reporting Period
This Form 8-K was filed by Anzu Special Acquisition Corp I, a special purpose acquisition company, regarding events reported July 29, 2022, with certain resignations effective July 31, 2022. The metadata identifies Envoy Medical, Inc., but the filing registrant is Anzu Special Acquisition Corp I.
The company stated that it had no pending letter of intent and provided no assurance that it would complete a business combination.
Financial Metrics and Liquidity
The filing does not provide a clear value for revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics. It states that the company was pursuing cost reductions and evaluating changes in potential acquisition targets.
Material Changes Versus the Prior Comparable Period
- Chief Financial Officer John W. Joy announced his resignation, effective after the company files its Form 10-Q for the quarter ended June 30, 2022.
- General Counsel and Corporate Secretary Peter J. Ganz resigned effective July 31, 2022.
- Director Teresa A. Harris resigned effective July 29, 2022, and director and Board Chairman William Wulfsohn resigned effective July 31, 2022.
- The Board was reduced from five directors to three.
- Following Ms. Harris’s resignation, the company was no longer compliant with Nasdaq’s requirement that its Audit Committee include at least three independent directors.
Guidance, Outlook, Risks, and Unusual Items
- The company cited changes in strategic direction, including the acquisition targets it was evaluating, as a reason for Mr. Joy’s resignation.
- Mr. Ganz’s resignation was attributed in part to cost cutting and changes in the company’s target-acquisition strategy.
- Ms. Harris and Mr. Wulfsohn cited disagreements with company decisions and processes, the loss of key executives, the nature and approach to potential acquisition candidates, changing market conditions, the approaching business-combination deadline, and the continued pursuit of a specific transaction.
- Nasdaq notified the company on August 2, 2022 that it did not comply with the independent-director and Audit Committee requirements. The company is entitled to a cure period and expected to regain compliance by its expiration.
- The company stated that no assurance could be given that it would complete a business combination. Forward-looking statements are subject to risks disclosed in its Form 10-K for the year ended December 31, 2021 and subsequent filings.
Key Facts for Investors to Verify
- Confirm the effective date and successor arrangements for the CFO and General Counsel positions.
- Verify whether the Board and Audit Committee were reconstituted within Nasdaq’s cure period.
- Review subsequent filings for developments regarding the company’s acquisition target, business-combination deadline, and any letter of intent.
- Assess the impact of the executive and director departures on transaction execution, governance, and compliance.
- Review the cited Form 10-K and subsequent SEC filings for liquidity, redemption, deadline, and business-combination risks.